Barbara Klencke, M.D.

Senior Vice President, Clinical Development, Onyx Pharmaceuticals

Barbara KlenckeBarb joined Onyx 2 years ago, where she has lead the development organization in the submission and subsequent approval of Kyprolis, a proteasome inhibitor for relapsed and refractory multiple myeloma.  Prior to joining Onyx, she lead a number of oncology development programs over the course of 8 years at Genentech. She received her MD degree from U.C. Davis and completed her internal medicine and hematology/oncology training at U.C. San Francisco, where she also held a faculty position as a medical oncologist and clinical researcher.   With a total of 2 decades of patient care experience prior to joining industry, she has a strong interest in the process of clinical research and in advances that have the potential to transform the lives of patients with cancer.